Affiliation:
1. N. N. Petrov National Medical Research Centre of Oncology, Ministry of Health of Russia
Abstract
BRCA-associated triple-negative breast cancer (TNBC) is characterized by high sensitivity to DNA-damaging cytotoxic drugs. The use of well-known BRCA1/2-specific antitumor agents – platinum derivatives and PARP inhibitors – has been discussed for a long time in the context of the treatment of metastatic BRCA-associated TNBC. Neoadjuvant regimens based on the use of anthracyclines and taxanes are the standard of drug therapy for primary BRCA-associated breast cancer. At present, there are few data regarding the addition of platinum drugs to anthracycline-taxane neoadjuvant chemotherapy in the treatment of primary BRCA-associated TNBC. This review details the various treatment options for both primary and metastatic BRCA-associated TNBC. It has been shown that the development of new strategies for the neoadjuvant chemotherapy of patients with primary BRCA-associated TNBC is an urgent clinical need to reduce the risks of recurrence and progression.
Publisher
Publishing House ABV Press
Subject
Cancer Research,Biochemistry (medical),Genetics (clinical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference50 articles.
1. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Moscow: P.A. Herzen Institute of Medical Research – branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of Russia, 2022. 252 p. (In Russ.).
2. Desai N.V., Tung N.M. Medical management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier. Breast J 2020; 26(8):1506–12. DOI: 10.1111/tbj.13972
3. Miki Y., Swensen J., Shattuck-Eidens D. et al. Strong candidate for the breast and ovarian cancer. Science 1994;266(5182):66–71. DOI: 10.1126/science.7545954
4. Wooster R., Neuhausen S.L., Mangion J. et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265(5181):2088–90. DOI: 10.1126/science.8091231
5. Antoniou A., Pharoah P.D., Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72(5):1117–30. DOI: 10.1086/375033